Both belong to a newer class of injectable treatments designed to address obesity and metabolic conditions, but they take slightly different approaches
In a carbohydrate-restricted state, the body increases reliance on fatty acid oxidation for energy
Its design enables selective receptor binding to GLP-1, GIP, and glucagon receptors to optimize metabolic impact balanced with side effects
Soon after approval: pricing may become clearer, but insurance requirements can still slow access
A Study of Retatrutide (LY3437943) in Participants With Obesity or Overweight
The reported result was the largest weight reduction recorded in a Phase 3 obesity trial pushing well beyond the 24.2% of the Phase 2 study and, in the higher-dose arm over the longer treatment window, into territory that puts a once-weekly injection in the same conversation as bariatric surgery